Hematologic Malignancies Market to Exhibit at a 10.7% CAGR during the forecast period 2022-2028 | Reports and Data

 Breaking News
  • No posts were found

Hematologic Malignancies Market to Exhibit at a 10.7% CAGR during the forecast period 2022-2028 | Reports and Data

September 26
19:18 2022
Hematologic Malignancies Market to Exhibit at a 10.7% CAGR during the forecast period 2022-2028 | Reports and Data
Hematologic Malignancies Market
The global hematologic malignancies market size is expected to reach USD 120.56 Billion by 2028 at a CAGR of 10.7%, according to the latest report by Reports and Data.

The global hematologic malignancies market size is expected to reach USD 120.56 Billion by 2028 at a CAGR of 10.7%, according to the latest report by Reports and Data. Rising prevalence of blood cancer, presence of strong pipeline therapeutics, and increasing expenditure in healthcare sector are key factors expected to drive market revenue growth over the forecast period. In addition, rapidly increasing geriatric population, rising awareness about early diagnosis and treatment, growing focus on developing advanced therapeutics, and increasing product approvals are expected to support market growth going ahead.

Hematologic malignancies are cancers that affect bone narrow, blood, and lymph nodes, and include different types of leukemia, myeloma, and lymphoma. Hematological malignancies account for nearly 9% of total newly diagnosed cancers in the United States. Blood cancer generally occur when there is rapid and uncontrollable growth of abnormal cells which interfere with development and functioning of normal cells. Hematologic malignancies are subdivided according to the type of blood cells that are affected. Lymphoblastic or lymphocytic malignancies occur in the lymphoid lineage, while myelogenous or myeloid malignancies occur in myeloid lineages. Treatment of hematologic malignancies is largely based on treating and alleviating symptoms. Aggressive hematologic malignancies require treatment with chemotherapy, immunotherapy, radiotherapy, and bone marrow transplant. increasing number of patients requiring chemotherapy and bone marrow transplant has increased over the recent past and this is expected to drive demand for these therapeutic approaches going ahead.

Over the last decade, numerous preclinical and clinical researches have generated encouraging results for treatment of hematological malignancies. Improved long-term outcomes for patients suffering from hematologic malignancies owing to rapid progress in therapeutics and drugs has contributed significantly to revenue growth of the market. Increasing funding and investment to accelerate cancer research is also expected to drive market growth. However, high costs of treatment and lack of skilled professionals is expected to restrain market growth to a certain extent over the forecast period.

Some Key Highlights From the Report:

  • Leukemia segment is expected to register robust revenue growth over the forecast period owing to increasing prevalence of leukemia across the globe, availability of advanced oncology drugs and therapeutics, and increasing collaborations in the market to boost development of advanced therapeutics for leukemia.
  •  
  • Chemotherapy segment is expected to account for largest revenue share during the forecast period, attributable to increasing application of chemotherapy in treatment of blood cancer. Chemotherapy is generally the first line of treatment for blood cancer and often uses a combination of drugs depending on the type of cancer.
  •  
  • North America is expected to account for largest revenue share between 2021 and 2028, attributable to rising prevalence of hematologic malignancies, establishment of robust healthcare facilities, availability of advanced cancer therapeutics, and robust presence of key market players in the region.
  •  
  • In April 2021, Arch Oncology, Inc., which is a clinical-stage oncology firm engaged in discovery and development of anti-CD47 therapeutics, closed a Series C round of financing at USD 105 Million. The funding will be used to accelerate clinical progress of differentiated anti-CD47 candidate for treating patients with solid tumors and hematologic malignancies.

 

Competitive Landscape:

The report also focuses on details of each market player including its global position, financial standing, revenue generation, company overview, product & service portfolio. The Hematologic Malignancies market is extremely competitive and consists of several key players at regional and global level. Key players are focused on adopting various strategies such as new product launches, mergers and acquisitions, investments in R&D, partnerships, joint ventures and collaborations to strengthen their market position and enhance product portfolio.

Leading companies operating in the market are:

Pfizer, Inc., F. Hoffmann-LA Roche ltd., Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation, Johnson & Johnson Services, Inc., and Takeda Pharmaceutical Company Limited.

 

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.reportsanddata.com/sample-enquiry-form/4056

The report also offers detailed insights about market segmentation based on type, application and regional bifurcation:

Hematologic Malignancies Market Segmentation:

Type Outlook (Revenue, USD Billion; 2018-2028)

  • Leukemia
    • Acute Lymphocytic Leukemia
    • Chronic Lymphocytic Leukemia
    • Acute Myeloid Leukemia
    • Chronic Myeloid Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Others

Therapy Outlook (Revenue, USD Billion; 2018-2028)

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others

 

Geographic Segment Covered in the Report:

The Hematologic Malignancies report provides information about the market area, which is further subdivided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate of each region, country, and sub-region during the estimated period.

• North America (the USA and Canada)

• Europe (UK, Germany, France, and the rest of Europe)

• Asia Pacific (China, Japan, India, and the rest of the Asia Pacific region)

• Latin America (Brazil, Mexico, and the rest of Latin America)

• the Middle East and Africa (GCC and the rest of the Middle East and Africa)

Key market aspects are illuminated in the report:

  • Executive Summary: It covers a summary of the most vital studies, the Global Hematologic Malignancies market increasing rate, modest circumstances, market trends, drivers and problems as well as macroscopic pointers.
  • Study Analysis: Covers major companies, vital market segments, the scope of the products offered in the Global Hematologic Malignancies market, the years measured, and the study points.
  • Company Profile: Each Firm well-defined in this segment is screened based on a products, value, SWOT analysis, their ability and other significant features.
  • Manufacture by Region: This Global Hematologic Malignancies report offers data on imports and exports, sales, production and key companies in all studied regional markets.

 

Thank you for reading the report. Kindly note that we also offer customized reports according to the client’s requirements. Contact us to know more about the customization feature and our team will provide you with the best-customized report. 

Explore More Industry Research by Reports and Data:

Burn Care Market @ https://www.reportsanddata.com/report-detail/burn-care-market 

Atropine Market @ https://www.reportsanddata.com/report-detail/atropine-market 

Esomeprazole Sodium Market @ https://www.reportsanddata.com/report-detail/esomeprazole-sodium-market 

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.

Media Contact
Company Name: Reports and Data
Contact Person: John Watson
Email: Send Email
Phone: +1-212-710-1370
Address:40 Wall St. 28th floor
City: New York City
State: NY 10005
Country: United States
Website: https://www.reportsanddata.com/report-detail/hematologic-malignancies-market

Related Articles

Categories